Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/Ib BEZ235 oral daily dosing study in advanced solid tumors and HER2-positive breast cancer
NL-OMON57811Phase 1Completed
- Sponsor
- Novartis
- Start
- Apr 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of dactolisib in Nonhematologic neoplasms, breast cancer and Cowden syndrome (CS) (2 arms), sponsored by Novartis. Primary endpoints: Incidence rate of dose-limiting toxicities and Safety and tolerability at maximum tolerated dose. Started Apr 2011; status: completed.
02
Drugs
dactolisib
03
Conditions
Nonhematologic neoplasmsbreast cancerCowden syndrome (CS)
Beyond the preview
Go deeper on NL-OMON57811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON57811.